Pipeline Insight: Molecular Targeted Cancer Therapies Can Anything Else Revolutionize The Market? : Market Research Report

Pipeline Insight: Molecular Targeted Cancer Therapies Can Anything Else Revolutionize The Market?

Published by: Datamonitor

Published: Oct. 23, 2007 - 434 Pages

About the PharmaVitae team
CHAPTER 1 EXECUTIVE SUMMARY: Key findings; Introduction to the PharmaVitae universe; The outlook for the market is challenging; Market performance is shaped by key ATC classes; The three fundamental dimensions of pharma space; Dimension one: molecule type analysis; MAbs and therapeutic proteins to provide the greatest overall sales growth; Generic erosion wipes out small molecule drug sales; mAbs driven by 'core' sales; Dimension two: therapy area analysis; Oncology and AIID products drive growth across 2006-12; GI and CV particularly badly hit in 2012; Targets provide a missing link between drugs and disease; Target classification; Dimension three: target family analysis; ECS target family set for superior performance; Only the ECS target family will see growth between 2011-12 (the 'patent cliff'); Position within the three fundamental dimensions of pharma space influences commercial outlook; Introduction; Novel targets offer reduced competitive pressures; Superior commercial outlook with increasing target novelty; New technologies allow expansion into novel target space; Market growth driven by biologics acting on ECS targets; Biologics offer insulation from generic erosion; ECS shielded from generics; Lifecycle stage dictates performance of small molecule drugs; Areas of high unmet need facilitate commercial success; Biologics more warranted in areas of high unmet need; Certain areas already saturated by cheap options; Perfomance relates to the balance of key characteristics; Commercial attractiveness characteristics; Not all volumes of pharma space are biologically viable; Mechanism of disease dictates the pharmacologically useful targets; Small molecule drugs cannot modulate ECS targets; Biologics cannot access the targets relating to certain diseases; ATC performance is driven by key characteristics; Segment 1: High growth biologics; Segment 2: Declining small molecule drugs; Segment 3: High growth small molecule drugs; Considerations beyond 2012; The need for new technologies; DNA/RNA therapies hit the central dogma of biology; Gene therapy; RNA therapies
CHAPTER 2 MARKET ANALYSIS: Key findings; Introduction; Total market overview; Growth drivers and resistors; Top 25 growth drivers across 2006-12; Top 25 growth resistors across 2006-12; Top 25 growth drivers 2012; Top 25 growth resistors 2012; Molecule type analysis; Small molecule drugs account for the bulk of sales; Generic substitution is greater where more generic alternatives are available; Products satisfying high unmet needs are more likely to gain market share; Biologic products will make a greater contribution to growth; Therapy area analysis; Therapy area growth drivers and resistors; Oncology and AIID drive growth; CV and GI set to decline overall; 2006-11 performance; 2012 performance; LCE profile
CHAPTER 3 TARGET FAMILY CLASSIFICATION: Key findings; Introduction; Targets are a key dimension of pharma space; The druggable genome; Druggability by small molecules-the Rule of Five.; Target family classification; GPCR target family; Introduction; Structure and function; Subfamilies; Ion channel target family; Introduction; Structure and function; Subfamilies; Nuclear receptor target family; Introduction; Structure and function; Subfamilies; Enzyme target family; Introduction; Structure and function; Subfamilies; Extracellular signaling (ECS) target family; Introduction; Structure and function; Subfamilies; Non-human; Other; Mixed; Unclassified
CHAPTER 4 MARKET ANALYSIS BY TARGET FAMILY: Key findings; Overview; Target family performance; ECS target family driving overall market growth; Enzyme and GPCR target families take the greatest hit in 2012; Therapy area analysis: satisfaction of unmet needs drives success; GPCR targets take the largest share of the CV and CNS sales; CV therapy area set for 'boom and bust'; Without target innovation, CNS products struggle to offset expiries; ECS targets drive growth of the oncology and AIID therapy areas; Falling sales of enzyme modulators bring down GI; Molecule type analysis; Monoclonal antibody (mAb) sales are driven by ECS targets; Therapeutic protein analysis; Small molecule drugs are highly susceptible to generic erosion; Vaccine sales are entirely derived from non-human targets; LCE analysis; Launch; Core; Expiry
CHAPTER 5 NUCLEAR RECEPTOR AND ION CHANNEL TARGET FAMILIES: Key findings; Overview: nuclear receptor and ion channel target families; Contribution to total market sales is set to diminish further; Ranked amongst the smallest target families by sales; Forecast to experience the fastest rate of decline; Scope for expansion is restricted; Small number of possible nuclear receptor target types; Nuclear receptors are not readily targeted by biologics; Ion channels offer significant potential, but are limited by their high association with CNS disorders; Therapy area analysis: key areas dictate overall performance; Diabetes & endocrinology pulls down nuclear receptor-related sales; Diabetes sales are pulled down by genericization of just one target type; Women's health products generate growth for the nuclear receptor target family; Growth despite limited target innovation; Tougher times ahead?; CNS pulls down ion channels; CNS is the largest ion channel therapy area by sales; New launches are not sufficient to overcome the decline of older products; Competition high due to lack of target innovation; Products not revolutionizing the satisfaction of unmet needs; Molecule type analysis: exclusively small molecule; LCE analysis: expiries drag sales into decline
CHAPTER 6 EXTRACELLULAR SIGNALLING PROTEIN (ECS) TARGET FAMILY: Key findings; Overview: ECS target family; Fastest rate of growth over 2006-12; Only target family to see growth in 2012; Therapy area analysis: driving growth of AIID & oncology; AIID sales growth is entirely reliant on ECS targets; Sales are largely derived from products acting on TNF-á; Novel targets generate growth as anti-TNF market slows; Novel ECS targets drive oncology growth; Success drawn from 'locking competitors out' of key targets; Molecule type analysis: new technologies opened up ECS targets; MAb technology has allowed novel ECS targets to be exploited; Unique position compared to other target families; Potential small molecule threat?; LCE analyis: growth across all LCE components; Expansion through novel targets; Free from declining 'expiry' sales
CHAPTER 7 ENZYME AND GPCR TARGET FAMILIES: Key findings; Overview: enzyme and GPCR target families; The largest target families by sales; Forecast to see the greatest decline over 2011-12; Therapy area analysis: novel targets drive growth; Enzyme sales growth wiped out by declining therapy areas.; Novel targets drive oncology sales and the enzyme target family; Transferase targets drive oncology therapy area growth; Tyrosine kinase inhibitors exemplify novel target value; Tyrosine kinase inhibitors account for the bulk of enzyme target family gains; GI and CV sales hit by loss of patents on key classes; Heavily reliant on ageing PPIs, GI sales are set decline; HMG-CoA reductase inhibitors erode enzyme target family growth; GPCR sales growth across all therapy areas but eroded in 2012; Angiotensin II receptor antagonists drive CV growth but hit by genericization; New CNS launches do little to replace the loss of 'blockbusters'; Diabetes sales driven by novel targets; Molecule type analysis: almost entirely small molecule; LCE analysis: expiries offset growth; Significant 'launch' gains driven by availability of novel targets; Massive 'expiry' loss in 2012
CHAPTER 8 APPENDIX: Target sub-sub-families; GPCR sub-sub-families; Nuclear receptor sub-sub-families; Enzyme sub-sub-families; Details of mixed and unclassified; Avandia; References; Journals; Websites; Abbreviations

Abstract

Introduction

Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.

Scope

Research and analysis of the MTT pipeline with in-depth clinical and commercial assessment of Phase III candidates Seven major pharmaceutical market sales forecasts to 2016 for key pipeline candidates incorporating product specific assumptions and events Segmentation and examination of product pipeline by developmental phase, class, mode of action, indication and developer Insight and analysis of market potential including commercial opportunity, commonalities across cancers and discussion of unmet needs

Highlights

329 different pipeline candidates have been identified of which 24 are in late-phase development. These identified candidates have a forecast sales potential of up to $6.03 billion in the seven major pharmaceutical markets by 2016. Among agents with the greatest commercial potential are the angiogenesis inhibitors Recentin (cediranib; AstraZeneca), aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and pazopanib (GlaxoSmithKline). Other candidates holding particular promise include the only preregistered agent Novartis's Gleevec-follow-on Tasigna (nilotinib), Novartis's mTOR inhibitor Certican (everolimus), and Biogen Idec's anti-CD23 monoclonal antibody, lumiliximab.

Reasons to Purchase

Acquire a detailed appreciation and impartial perspective of the entire molecular targeted therapies developmental pipeline Identify the key products in late-phase development based on sales forecasts to 2016 and Datamonitor's drug assessment methodology Assess the shifting oncology market dynamic and how future treatment of many cancers will incorporate pipeline products

Please Note: This product is delivered as a zip file,

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Pipeline Insight: Molecular Targeted Cancer Therapies Can Anything Else Revolutionize The Market?

Table of Contents

Abstract